Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-1 + epirubicin + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
S-1 + epirubicin + oxaliplatin is a combination chemotherapy regimen primarily investigated for the treatment of advanced or metastatic gastric and esophagogastric cancer. S-1 is an oral fluoropyrimidine consisting of tegafur (a prodrug of 5-fluorouracil), 5-chloro-2,4-dihydroxypyridine (a dihydropyrimidine dehydrogenase inhibitor that prolongs 5-FU exposure), and oteracil potassium (which reduces gastrointestinal toxicity). Epirubicin is an anthracycline antineoplastic that intercalates DNA and inhibits topoisomerase II. Oxaliplatin is a platinum-based agent that forms DNA crosslinks, resulting in apoptosis. This combination leverages the distinct mechanisms of each agent for enhanced antitumor efficacy, particularly in first-line palliative therapy of advanced gastric cancers[1][3][2][4].
- Brand names
- Teysuno
- Other names
- tegafur/gimeracil/oteracil + epirubicin + oxaliplatinS-1 + epirubicin + oxaliplatin
02
Targets
TOP2A (DNA topoisomerase II)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on S-1 + epirubicin + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-1 + epirubicin + oxaliplatin.